Ads
related to: meningococcal encephalitis vaccine
Search results
Results From The WOW.Com Content Network
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [ 9 ] [ 10 ] The vaccines are between 85 and 100% effective for at least two years. [ 9 ]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
A new vaccine from Pfizer has been approved by the Food and Drug Administration as the first shot of its kind to address multiple strains of meningococcal disease, the company said Oct. 20.. After ...
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
Meningococcal diseases are rare bacterial infections that commonly affect the brain, spinal cord and bloodstream, and can be deadly in a matter of hours. The pentavalent vaccine protects against ...
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
Ads
related to: meningococcal encephalitis vaccine